证券代码：300685 证券简称：艾德生物 公告编号：2024-061 2、审议通过《关于选举公司第四届监事会主席的议案》 第四届监事会第一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 第四届监事会第一次会议系于2024年8月14日在公司召开的2024年第二次临 时股东大会选举产生第四届监事会非职工代表监事后，经全体监事同意豁免会议 通知时间要求，以电话、口头等方式通知了全体监事。公司第四届监事会第一次 会议于2024年8月14日在厦门市海沧区鼎山路39号公司会议室以通讯和现场表 决相结合的方式召开，会议应到监事3人，实到监事3人，符合公司章程规定的 法定人数。会议的通知和召开符合《公司法》与《公司章程》的规定。本次会议 全体监事推举监事王弘宇先生主持。 二、监事会会议审议情况 1、审议通过《关于豁免公司第四届监事会第一次会议通知期限的议案》 表决结果：3票赞成，0票反对，0票弃权，本议案获表决通过。 为提高工作效率，同意豁免公司第四届监事会第一次会议 ...

Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Views - The company demonstrates steady performance growth, with profit growth outpacing revenue growth after excluding the impact of equity incentives [2][4] - The company's diagnostic reagents maintain strong growth, while drug clinical research services are rapidly expanding [2][7] - The company has established a comprehensive companion diagnostic product system from targeted therapy to immunotherapy, positioning itself as a leader in the field of tumor precision diagnosis [2][7] - The company is accelerating its international market expansion, with recent collaborations with global pharmaceutical giants such as Boehringer Ingelheim and Servier [7][8] Financial Performance - In H1 2024, the company achieved revenue of 543 million yuan (+18.4% YoY), net profit attributable to shareholders of 144 million yuan (+13.5% YoY), and non-GAAP net profit of 132 million yuan (+20.7% YoY) [2][4] - Excluding the impact of equity incentive expenses, H1 2024 net profit attributable to shareholders would be 161 million yuan (+26.78% YoY), and non-GAAP net profit would be 149 million yuan (+36.13% YoY) [2][4] - The company's gross margin improved to 85.2% (+1.5pp YoY) in H1 2024, with R&D expenses accounting for 19.6% of revenue [9] - The company's operating cash flow remained healthy, with a net operating cash flow of 139 million yuan in H1 2024, representing 96.7% of net profit attributable to shareholders [10] Business Segments - Diagnostic reagents revenue reached 448 million yuan (+16.8% YoY) in H1 2024, with a gross margin of 90.9% (+0.4pp YoY) [7] - Drug clinical research services revenue surged to 60 million yuan (+136.1% YoY) in H1 2024, with a gross margin of 63.0% (+2.0pp YoY) [7] - Domestic sales accounted for 413 million yuan (+16.0% YoY), while international sales and BD business reached 130 million yuan (+26.5% YoY) in H1 2024 [7] Valuation and Forecast - The report slightly revised down the profit forecast, expecting net profit attributable to shareholders of 319/393/482 million yuan for 2024-2026, representing YoY growth of 21.9%/23.2%/22.7% [10] - The current stock price corresponds to a PE ratio of 23/19/15 times for 2024-2026 [10] - The company's ROE is expected to improve from 16.3% in 2024E to 18.2% in 2026E [1]

Investment Rating - The report maintains a "Cautious Recommendation" rating for the company [1]. Core Views - The company reported a revenue of 543 million yuan for the first half of 2024, representing an 18.38% increase year-on-year, and a net profit attributable to shareholders of 144 million yuan, up 13.49% [1]. - The company continues to benefit from the return of testing services to hospitals, with a significant increase in revenue from testing reagents and a strong gross margin [1]. - The company has expanded its tumor detection solutions through various precision medical technology platforms, having developed 27 tumor gene detection products approved in China [1]. - The company has established partnerships for companion diagnostics with numerous well-known pharmaceutical companies, leading to rapid growth in international sales [1]. Financial Performance Summary - For the first half of 2024, the company achieved a revenue of 543 million yuan (+18.38%) and a net profit of 144 million yuan (+13.49%) [1]. - The revenue from testing reagents was 448 million yuan (+16.75%), while the revenue from testing services decreased to 32 million yuan (-28.01%) [1]. - The company invested 106 million yuan in research and development, accounting for 19.56% of its revenue [1]. Financial Forecast - The company is projected to achieve revenues of 1,279.14 million yuan in 2024, with a growth rate of 22.58% [6]. - The net profit attributable to shareholders is expected to reach 325.39 million yuan in 2024, reflecting a growth rate of 24.44% [6]. - The projected EPS for 2024 is 0.82 yuan, with a PE ratio of 23.16 [6].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 26.60 RMB [1][3] Core Views - The company's performance met expectations, with notable profitability after excluding equity incentive expenses In H1 2024, the company achieved revenue of 540 million RMB, a YoY increase of 18.4%, and net profit attributable to shareholders of 140 million RMB, a YoY increase of 13.5% Excluding equity incentive expenses, the net profit attributable to shareholders was 160 million RMB, a YoY increase of 26.8% [1] - Domestic sales revenue reached 410 million RMB, a YoY increase of 16.0%, while international sales and pharmaceutical business revenue reached 130 million RMB, a YoY increase of 26.5% [1] - The company's R&D efforts are efficient, with over 15% of revenue consistently invested in R&D The company has developed and obtained approval for 27 tumor gene detection products in China, and new products such as the real-time fluorescence quantitative PCR analyzer were approved in June 2024 [1] - The company has established partnerships with Boehringer Ingelheim and Servier to develop companion diagnostic products, expanding its innovative business areas [1] - Gross margin improved to 85.2% in H1 2024, a YoY increase of 1.5 percentage points, while sales and R&D expense ratios decreased to 29.5% and 19.6%, respectively [1] Financial Performance and Forecast - Revenue for 2024 is forecasted to be 1,279 million RMB, with a YoY growth of 22.6% Net profit attributable to shareholders is expected to reach 303 million RMB, a YoY increase of 15.9% [2] - Gross margin is projected to remain stable at 86.0% from 2024 to 2026, with net profit margins of 23.7%, 25.1%, and 24.6% for the respective years [2] - The company's ROE is expected to improve from 16.4% in 2024 to 18.0% in 2026 [2] Valuation and Peer Comparison - The company's 2024 PE ratio is estimated at 24.9, with a target price of 26.60 RMB based on a 35x PE multiple [1][3] - Compared to peers, the company's valuation is in line with industry averages, with adjusted average PE ratios of 35 for 2024 and 25 for 2025 [5] Business Segments - Detection reagent revenue accounted for 450 million RMB, a YoY increase of 16.8%, while detection service revenue declined by 28.0% to 30 million RMB Drug clinical research service revenue surged by 136.1% to 60 million RMB [1] Growth and Profitability - The company's revenue growth is expected to remain strong, with projected YoY growth rates of 22.6%, 21.0%, and 21.4% for 2024, 2025, and 2026, respectively [2] - Operating profit is forecasted to grow by 11.8% in 2024, 28.4% in 2025, and 19.0% in 2026 [2]

厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 于2024年2月26日召开2024年第一次临时股东大会，审议通过了《关于以集中竞 价交易方式回购公司股份的议案》。根据本次回购方案，公司拟使用自有资金以 集中竞价方式回购股份用于注销并减少公司注册资本；回购资金总额为不低于人 民币10,000万元且不超过人民币20,000万元，具体回购资金金额以回购实施完成 时实际回购的金额为准；回购股份的实施期限为自公司股东大会审议通过本次回 购方案之日起12个月内。具体内容详见公司于2024年2月26日刊登在巨潮资讯网 的《回购报告书》。 根据《深圳证券交易所上市公司自律监管指引第 9 号—回购股份》等相关规 定，现将公司回购股份的进展情况公告如下： 证券代码：300685 证券简称：艾德生物 公告编号：2024-058 厦门艾德生物医药科技股份有限公司 关于回购股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 （1）委托价格不得为公司股票当日交易涨幅限制的价格； （2）不得在深圳证券交易所开盘集合竞价、收盘集合竞价及股票价格无涨 跌幅限制的 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 17.77 yuan [3][5] Core Viewpoints - The company, as a leading player in the domestic tumor companion diagnostics industry, continues to show strong growth in performance driven by innovation and partnerships [3] - The company's R&D investment has increased significantly, with a 15.62% YoY growth in H1 2024, accounting for 19.56% of total revenue [2] - The company has expanded its strategic partnerships, including collaborations with Boehringer Ingelheim and Servier, to advance innovation in companion diagnostics [13] Financial Performance - Revenue for H1 2024 reached 543 million yuan, up 18.38% YoY, with domestic revenue at 413 million yuan (up 16.02% YoY) and international revenue at 130 million yuan (up 26.51% YoY) [12] - Net profit attributable to shareholders in H1 2024 was 144 million yuan, up 13.49% YoY, while adjusted net profit grew 20.72% YoY [12] - Revenue from drug clinical research services surged 136.07% YoY, contributing significantly to overall growth [12] R&D and Innovation - The company's R&D investment in H1 2024 was 106.212 million yuan, up 15.62% YoY, with 27 Class III medical device registrations and 65 patents (59 invention patents and 6 utility model patents) [2] - A real-time fluorescent quantitative PCR analyzer obtained Class III medical device registration in June 2024, enhancing the company's tumor precision detection solutions [2] Valuation and Forecast - The report forecasts net profit attributable to shareholders for 2024-2026 at 315 million yuan, 379 million yuan, and 454 million yuan, respectively, with corresponding P/E ratios of 22x, 19x, and 16x [3] - Revenue is expected to grow steadily, with projected revenue for 2024-2026 at 1.519 billion yuan, 1.835 billion yuan, and 2.166 billion yuan, respectively [4] - EPS is forecasted to increase from 0.79 yuan in 2024 to 1.14 yuan in 2026 [4] Strategic Partnerships - In May 2024, the company signed a new companion diagnostics collaboration with Boehringer Ingelheim to identify non-small cell lung cancer patients likely to benefit from targeted therapy [13] - In June 2024, the company announced a strategic partnership with Servier to develop a companion diagnostic reagent for detecting IDH1 and IDH2 gene mutations [13]

Summary of Conference Call Company Overview - The company discussed is Aide Biotechnology, recognized as a leading player in the domestic companion diagnostics sector. [1] Core Points and Arguments - Aide Biotechnology has a comprehensive product line that caters to the growing demand for companion diagnostics in China. [1] - The company is expected to experience long-term growth due to the continuous increase in domestic demand and the expansion of its overseas market. [1] Additional Important Content - The presentation included an introduction to the performance forecast for the first half of 2024, indicating a positive outlook for the company's future development. [1]

公司点评报告 ·医药行业 2024年7月30日 请务必阅读正文最后的中国银河证券股份有限公司免责声明 公司点评报告 · 医药行业 公司点评报告 · 医药行业 核心观点 www.chinastock.com.cn 河证券|CGS 请务必阅读正文最后的中国银河证券股份有限公司免责声明。 E券|CGS 臂业收入 营业利润 归属母公司净利润 毛利率 净利率 ROE ROIC 资产负债率 净负债比率 流动比率 速动比率 应收账款周转率 应付账款周转率 每股收益 每股净资产 P/E P/B EV/EBITDA P/S 2023A 2024E 2025E 2026E 23.91% 22.58% 21.84% 20.18% 4.72% 22.13% 22.60% 20.74% -0.86% 24.44% 22.67% 20.54% 83.97% 84.00% 85.38% 85.27% 25.06% 25.44% 25.69% 25.61% 15.35% 16.78% 17.07% 17.07% 14.71% 15.25% 15.54% 15.53% 11.97% 10.22% 9.04% 8.31% -29.13% -34 ...

24H1 业绩符合预期，院内业务稳健增长 2024 年中报业绩点评 2024年7月30日 www.chinastock.com.cn 请务必阅读正文最后的中国银河证券股份有限公司免责声明 公司点评报告 · 医药行业 请务必阅读正文最后的中国银河证券股份有限公司免责声明。 正券|CGS 主要财务比率 臂业收入 营业利润 归属母公司净利润 毛利率 降利率 ROE ROIC 资产负债率 净负债比率 流动比率 速动比率 总资产周转率 应收账款周转率 应付账款周转率 每股收益 每股经营现金 每股净资产 P/E P/B EV/EBITDA P/S 请务必阅读正文最后的中国银河证券股份有限公司免责声明。 公司点评报告 · 医药行业 本报告由中国银河证券股份有限公司（以下简称银河证券）向其客户提供。银河证券无需因接收人收到本报告而视其为客户。 若悠并非银河证券客户中的专业投资者,为保证服务质量、控制投资风险、应首先联系银河证券机构销售部门或客户经理、完成投 资者适当性匹配,并充分了解该项服务的性质、特点、使用的注意事项以及若不当使用可能带来的风险或损失。 本报告所载的全部内容只提供给客户做参考之用，并不构成对客户的投资咨询建 ...

Investment Rating - The report maintains a "Buy" rating for the company [3][14]. Core Views - The company achieved steady growth in domestic markets while experiencing rapid growth in overseas markets and pharmaceutical business [14]. - The performance in Q2 met expectations, with a revenue of 543 million yuan (+18.38%) and a net profit of 144 million yuan (+13.49%) for H1 2024 [14]. - The company continues to enhance its market share in hospitals through compliance products and is developing LDT products in response to market needs [14]. Financial Summary - For H1 2024, the company reported: - Revenue from testing reagents: 448 million yuan (+16.75%), with a gross margin of 90.89% (+0.35 percentage points) - Revenue from testing services: 32 million yuan (-28.01%), with a gross margin of 51.46% (+8.51 percentage points) [14]. - The company’s revenue forecast for 2024-2026 is 1.275 billion yuan, 1.552 billion yuan, and 1.886 billion yuan respectively, with expected growth rates of 22.2%, 21.7%, and 21.5% [15]. - The net profit forecast for 2024-2026 is 291 million yuan, 380 million yuan, and 493 million yuan respectively, with growth rates of 11.3%, 30.8%, and 29.5% [15]. Market Expansion - The international market and pharmaceutical business revenue reached 130 million yuan (+26.51%), with successful establishment of subsidiaries in Singapore and Canada, and a logistics center in the Netherlands [14]. - The company is actively participating in clinical trials for several well-known pharmaceutical companies, which is expected to drive long-term growth [14]. Research and Development - The company invested 106 million yuan in R&D (+15.62%), accounting for 19.56% of revenue, and has a rich pipeline of new products under development [14]. - New products under registration include various gene testing kits and antibody reagents, which are anticipated to become new growth points upon market launch [14].